The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients

Document Type : Original Articles

Authors

1 Northern Technical University, College of Health and Medical Technology, Kirkuk, Iraq

2 Middle Technical University, College of Health and Medical Technology, Baghdad, Iraq

3 Middle Technical University, Institute of Technical Medicine, Baghdad, Iraq

Abstract

Breast cancer is a common women malignancy worldwide. Emerging evidence suggests that various complement molecules function as an immune suppressors in the tumor microenvironment (TME). Therefore this study aimed to investigate the role of the anaphylatoxins C3a and C5a in the propagation of breast cancer and their relationships with clinicopathological factors in Iraqi women suffering from breast tumors. ELISA technique was used to determine the serum anaphylatoxins C3a and C4a levels in 60 Iraqi women with breast tumors (30 with primary breast cancer and 30 with benign breast tumor) before surgery and treatment as 30 healthy controls. In addition, the clinicopathological factors of all the patients were collected. The result showed a significantly increased level of anaphylatoxins C3a and C5a (P<0.001) in primary breast cancer patients than in benign breast tumor and healthy control women. The area under the curve (AUC) of C3a and C5a for distinguishing patients with primary breast cancer and healthy control subjects was 0.878 (95% CI: 0.768 to 0.948) and 0.953 (95% CI: 0.865 to 0.991) respectively. C5a correlated with larger tumor size, lymph node metastasis, and histologic grade III, whereas C3a only with lymph node metastasis. In conclusion, preoperative levels of C5a exhibit high accuracy for primary breast cancer than C3a. C5a correlated with tumor burden more than C3a and suggested an enhancing effect of C5a on BC proliferation. Thus, suggesting prognostic value for C5a in primary BC.

Keywords

References

  1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. Cancer J Clin. 2020;70(3):145-64.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394-424.
  3. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I–molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
  4. Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65(1):500-43.
  5. Wang Y, Zhang H, He Y-W. The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy. Front Immunol. 2019;10:1574.
  6. Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer. 2019;19(12):698-715.
  7. Afshar-Kharghan V. The role of the complement system in cancer. J Clin Investig. 2017;127(3):780-9.
  8. Lu Y, Hu X-B. C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep. 2014;32(6):2817-23.
  9. Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT. Complement system: promoter or suppressor of cancer progression? Antibodies. 2020;9(4):57.
  10. West EE, Kunz N, Kemper C. Complement and human T cell metabolism: Location, location, location. Immunol Rev. 2020;295(1):68-81.
  11. Zhang X, Sun L. Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. Mol Clin Oncol. 2018;8(2):315-9.
  12. Shu C, Zha H, Long H, Wang X, Yang F, Gao J, et al. C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts. J Exp Clin Cancer Res. 2020;39(1):1-14.
  13. Davidson S, Efremova M, Riedel A, Mahata B, Pramanik J, Huuhtanen J, et al. Single-cell RNA sequencing reveals a dynamic stromal niche that supports tumor growth. Cell Rep. 2020;31(7):107628.
  14. Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, et al. Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer. 2016;23(6):876-85.
  15. Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, et al. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018;197(9):1164-76.
  16. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;189(9):4674-83.
  1. Xi W, Liu L, Wang J, Xia Y, Bai Q, Long Q, et al. High level of anaphylatoxin C5a predicts poor clinical outcome in patients with clear cell renal cell carcinoma. Sci Rep. 2016;6(1):1-8.
  2. Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Izumi D, et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget. 2016;7(51):84798.
  3. Chen J, Sun Z-h, Chen L-y, Xu F, Zhao Y-p, Li G-q, et al. C5aR deficiency attenuates the breast cancer development via the p38/p21 axis. Aging. 2020;12(14):14285.
  4. Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014;74(13):3454-65.

21.          van de Vijver MJ. Molecular tests as prognostic factors in breast cancer. Virchows Archiv. 2014;464(3):283-91. 

Archives of Razi Institute
Volume 77, Issue 5 - Serial Number 5
September and October 2022
Pages 1873-1879

Files

Share

How to cite

Statistics